Ramaswamy Madhu, Efimova Elena V, Martinez Osvaldo, Mulherkar Nirupama U, Singh Surya P, Prabhakar Bellur S
Department of Microbiology and Immunology, University of Illinois at Chicago, 835 South Wolcott Avenue, Chicago, IL 60612, USA.
Oncogene. 2004 Aug 12;23(36):6083-94. doi: 10.1038/sj.onc.1207804.
Recently, we identified Insulinoma-Glucagonoma clone 20 (IG20) that can render cells more susceptible to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis. In addition, it can slow cell proliferation, and enhance drug- and radiation-induced cell death. TNF-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in some cancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or no effect on most normal cells. In this study, we investigated the potential of IG20 to enhance TRAIL-induced apoptosis and found that it can render cells more susceptible to TRAIL treatment through enhanced activation of caspases. Further, we showed that this effect can be suppressed by caspase inhibitors, p35 and CrmA, and a dominant-negative Fas-associated death domain-containing protein (DN-FADD). Results from colocalization and immunoprecipitation studies showed that IG20 can interact with TRAIL death receptors (DR), DR4 and DR5 and increase recruitment of FADD and caspase-8 into the TRAIL death-inducing signaling complex (DISC). These results indicate that IG20 is a novel protein that can enhance TRAIL-induced apoptosis by facilitating DISC formation.
最近,我们鉴定出胰岛素瘤-胰高血糖素瘤克隆20(IG20),它可使细胞对肿瘤坏死因子-α(TNF-α)诱导的凋亡更敏感。此外,它能减缓细胞增殖,并增强药物和辐射诱导的细胞死亡。肿瘤坏死因子相关凋亡诱导配体(TRAIL)可在某些癌细胞中选择性诱导凋亡,并使其他癌细胞对药物和辐射联合治疗敏感,而对大多数正常细胞几乎没有影响。在本研究中,我们研究了IG20增强TRAIL诱导凋亡的潜力,发现它可通过增强半胱天冬酶的激活使细胞对TRAIL治疗更敏感。此外,我们表明这种效应可被半胱天冬酶抑制剂p35和CrmA以及显性负性含Fas相关死亡结构域蛋白(DN-FADD)抑制。共定位和免疫沉淀研究结果表明,IG20可与TRAIL死亡受体(DR)DR4和DR5相互作用,并增加FADD和半胱天冬酶-8募集到TRAIL死亡诱导信号复合物(DISC)中。这些结果表明,IG20是一种新型蛋白质,可通过促进DISC形成增强TRAIL诱导的凋亡。